Last reviewed · How we verify
Urothelial Cancer
Approved treatments
- Keytruda · Merck & Co.
Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response. - Keytruda · Merck & Co.
Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Urothelial Cancer patent landscape — cliff calendar, originator estates, attackable patents
- Urothelial Cancer treatment landscape brief
- Urothelial Cancer treatment updates RSS
Frequently asked questions about Urothelial Cancer
What drugs treat Urothelial Cancer?
Tracked treatments include Keytruda.
What is the treatment for Urothelial Cancer?
Standard treatment for Urothelial Cancer includes Keytruda. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Urothelial Cancer patent cliff · Urothelial Cancer CI report
- Treatment: Keytruda · Merck & Co.
- Treatment: Keytruda · Merck & Co.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing